Risk Factors for Rapid Cognitive Decline in Amyloid-Negative Individuals Without Cognitive Impairment or With Early-Stage Cognitive Loss in Screening Tests.

IF 9.6 3区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Clinical Nuclear Medicine Pub Date : 2024-11-01 Epub Date: 2024-07-31 DOI:10.1097/RLU.0000000000005384
Yong-Jin Park, Joon Young Choi, Kyung-Han Lee, Sang Won Seo, Seung Hwan Moon
{"title":"Risk Factors for Rapid Cognitive Decline in Amyloid-Negative Individuals Without Cognitive Impairment or With Early-Stage Cognitive Loss in Screening Tests.","authors":"Yong-Jin Park, Joon Young Choi, Kyung-Han Lee, Sang Won Seo, Seung Hwan Moon","doi":"10.1097/RLU.0000000000005384","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Although rapid cognitive decline (RCD) is an important unfavorable prognostic factor, not much is known about it, especially in amyloid-negative individuals. The purpose of this study was to investigate risk factors for RCD in amyloid-negative individuals.</p><p><strong>Patients and methods: </strong>We retrospectively enrolled 741 individuals who were either cognitively unimpaired or had early-stage cognitive ability loss and who underwent 18 F-florbetaben (FBB) (n = 402) or 18 F-flutemetamol (FMM) (n = 339) PET/CT. Based on visual and semiquantitative (SUV ratio [SUVR]-based) analysis, the following amyloid-negative groups were established: visual-negative FBB (n = 232), visual-negative FMM (n = 161), SUVR-negative FBB (n = 104), and SUVR-negative FMM (n = 101). Univariable and multivariable logistic regression analyses were performed for RCD using 5 SUVRs, 5 cortical thicknesses, and 5 neuropsychological domains and clinico-demographic factors.</p><p><strong>Results: </strong>In the amyloid-negative groups, a decline in language function was commonly identified as a significant risk factor for RCD ( P = 0.0044 in the visual-negative FBB group, P = 0.0487 in the visual-negative FMM group, P = 0.0031 in the SUVR-negative FBB group, and P = 0.0030 in the SUVR-negative FMM group). In addition, declines in frontal/executive function, frontal SUVR, and parietal SUVR; a longer duration of education; and mild cognitive decline in the amyloid-negative groups were also significant risk factors for RCD.</p><p><strong>Conclusions: </strong>Even in amyloid-negative individuals without cognitive impairment or with early-stage cognitive ability loss, those with decreased language and frontal/executive functions on neuropsychological testing are at risk of progression to RCD.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"1014-1024"},"PeriodicalIF":9.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/RLU.0000000000005384","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/31 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Although rapid cognitive decline (RCD) is an important unfavorable prognostic factor, not much is known about it, especially in amyloid-negative individuals. The purpose of this study was to investigate risk factors for RCD in amyloid-negative individuals.

Patients and methods: We retrospectively enrolled 741 individuals who were either cognitively unimpaired or had early-stage cognitive ability loss and who underwent 18 F-florbetaben (FBB) (n = 402) or 18 F-flutemetamol (FMM) (n = 339) PET/CT. Based on visual and semiquantitative (SUV ratio [SUVR]-based) analysis, the following amyloid-negative groups were established: visual-negative FBB (n = 232), visual-negative FMM (n = 161), SUVR-negative FBB (n = 104), and SUVR-negative FMM (n = 101). Univariable and multivariable logistic regression analyses were performed for RCD using 5 SUVRs, 5 cortical thicknesses, and 5 neuropsychological domains and clinico-demographic factors.

Results: In the amyloid-negative groups, a decline in language function was commonly identified as a significant risk factor for RCD ( P = 0.0044 in the visual-negative FBB group, P = 0.0487 in the visual-negative FMM group, P = 0.0031 in the SUVR-negative FBB group, and P = 0.0030 in the SUVR-negative FMM group). In addition, declines in frontal/executive function, frontal SUVR, and parietal SUVR; a longer duration of education; and mild cognitive decline in the amyloid-negative groups were also significant risk factors for RCD.

Conclusions: Even in amyloid-negative individuals without cognitive impairment or with early-stage cognitive ability loss, those with decreased language and frontal/executive functions on neuropsychological testing are at risk of progression to RCD.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
淀粉样蛋白阴性个体中认知能力迅速下降的风险因素,这些个体在筛查测试中未出现认知功能障碍或出现早期认知功能丧失。
目的:尽管快速认知功能衰退(RCD)是一个重要的预后不利因素,但人们对其了解不多,尤其是对淀粉样蛋白阴性患者。本研究的目的是调查淀粉样蛋白阴性患者出现快速认知衰退的风险因素:我们回顾性地招募了741名认知能力未受损或有早期认知能力丧失的患者,他们接受了18F-氟贝特宾(FBB)(n = 402)或18F-氟美他莫(FMM)(n = 339)PET/CT检查。根据肉眼和半定量(基于 SUV 比值 [SUVR])分析,确定了以下淀粉样蛋白阴性组:肉眼阴性 FBB(n = 232)、肉眼阴性 FMM(n = 161)、SUVR 阴性 FBB(n = 104)和 SUVR 阴性 FMM(n = 101)。利用5种SUVR、5种皮质厚度、5种神经心理领域和临床人口学因素对RCD进行了单变量和多变量逻辑回归分析:在淀粉样蛋白阴性组中,语言功能下降通常被认为是RCD的重要风险因素(视觉阴性FBB组P = 0.0044,视觉阴性FMM组P = 0.0487,SUVR阴性FBB组P = 0.0031,SUVR阴性FMM组P = 0.0030)。此外,淀粉样蛋白阴性组的额叶/执行功能、额叶SUVR和顶叶SUVR下降;受教育时间较长;以及轻度认知功能下降也是RCD的重要风险因素:结论:即使在没有认知障碍或早期认知能力丧失的淀粉样蛋白阴性个体中,那些在神经心理测试中语言和额叶/执行功能下降的个体也有进展为RCD的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Nuclear Medicine
Clinical Nuclear Medicine 医学-核医学
CiteScore
2.90
自引率
31.10%
发文量
1113
审稿时长
2 months
期刊介绍: Clinical Nuclear Medicine is a comprehensive and current resource for professionals in the field of nuclear medicine. It caters to both generalists and specialists, offering valuable insights on how to effectively apply nuclear medicine techniques in various clinical scenarios. With a focus on timely dissemination of information, this journal covers the latest developments that impact all aspects of the specialty. Geared towards practitioners, Clinical Nuclear Medicine is the ultimate practice-oriented publication in the field of nuclear imaging. Its informative articles are complemented by numerous illustrations that demonstrate how physicians can seamlessly integrate the knowledge gained into their everyday practice.
期刊最新文献
68Ga-Prostate-Specific Membrane Antigen PET/CT in Endometrial Cancer: A Preliminary Report. 99mTc-PSMA and 99mTc-FAPI-46 Uptake in Pulmonary Lymphangitic Carcinomatosis: A Rare Form of Metastasis in Prostate Cancer Patient, Responding to Modified Treatments. FDG PET Images of Pseudoprogression After Nivolumab-FOLFOX Chemotherapy in a Gastric Cancer Patient. FDG PET/CT Image of Extragastrointestinal Stromal Tumor in the Posterior Mediastinum. Pictorial Essay: 18F FDG Brain PET-MR in Congenital Brain Anomalies Presenting With Seizures.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1